William D. Tap, MD, Chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the potential to combine KIT and CTLA-4 blockade in patients with refractory GIST and other advanced sarcomas.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
Ещё видео!